Regeneron Pharmaceuticals

URI: https://gptkb.org/entity/Regeneron_Pharmaceuticals
GPTKB entity
Statements (53)
Predicate Object
gptkbp:instanceOf gptkb:biotechnology
gptkb:public_company
gptkbp:awarded gptkb:2020_Prix_Galien_USA_Award_for_Best_Biotechnology_Product_(EYLEA)
gptkb:2021_Prix_Galien_USA_Award_for_Best_Biotechnology_Product_(REGEN-COV)
gptkbp:CEO gptkb:Leonard_Schleifer
gptkbp:collaboratedWith gptkb:Bayer
gptkb:Sanofi
gptkbp:country gptkb:United_States
gptkbp:focusesOn immunology
infectious diseases
oncology
ophthalmology
rare diseases
gptkbp:foundedBy gptkb:George_Yancopoulos
gptkb:Leonard_Schleifer
gptkbp:foundedYear 1988
gptkbp:hasFacility gptkb:Limerick,_Ireland
gptkb:Rensselaer,_New_York,_United_States
gptkbp:hasPatent gptkb:VelociSuite_technologies
monoclonal antibody technologies
gptkbp:headquartersLocation gptkb:Tarrytown,_New_York,_United_States
https://www.w3.org/2000/01/rdf-schema#label Regeneron Pharmaceuticals
gptkbp:industry gptkb:biotechnology
pharmaceuticals
gptkbp:listedOn gptkb:NASDAQ
gptkbp:memberOf gptkb:Biotechnology_Innovation_Organization
gptkbp:netIncome $3.4 billion (2023)
gptkbp:numberOfEmployees ~11,800
gptkbp:President_and_CSO gptkb:George_Yancopoulos
gptkbp:product gptkb:Dupixent_(dupilumab)
gptkb:Praluent_(alirocumab)
gptkb:REGEN-COV_(casirivimab_and_imdevimab)
EYLEA (aflibercept)
Kevzara (sarilumab)
Libtayo (cemiplimab)
gptkbp:researchInterest genetics
immunology
oncology
ophthalmology
gene editing
RNA therapeutics
antibody therapeutics
gptkbp:revenue $13.1 billion (2023)
gptkbp:stockExchange gptkb:S&P_500
gptkbp:stockSymbol gptkb:REGN
gptkbp:subsidiary gptkb:Regeneron_Ireland
gptkbp:tradedOn gptkb:NASDAQ:_REGN
gptkbp:website https://www.regeneron.com/
gptkbp:bfsParent gptkb:Intellia_Therapeutics
gptkb:NASDAQ-100
gptkb:Sir_John_Bell
gptkb:NOVN
gptkbp:bfsLayer 5